Angiocentric T-cell lymphoma presenting as midface destructive lesion: case report and literature review.
A case of angiocentric T-cell lymphoma presenting as a midface destructive lesion is reported. Angiocentric T-cell lymphoma typically manifests as an aggressive, progressively destructive, and necrotizing disorder, often with a fatal outcome. This case was characterized microscopically by the presence of an atypical lymphoid population that expressed a CD45+, CD3+ cytoplasmic, CD5+, and CD56- T-cell phenotype within a background of a polymorphous inflammatory infiltrate. Because of the rarity of the disorder, the differential diagnosis is discussed. Recent advances in clinical immunodiagnostics, the variations in therapeutic modalities, and the prognosis of the disease as reported in the recent literature are reviewed.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008444:Maxillary Sinus Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008875:Middle Aged; D009669:Nose Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery; D010157:Palatal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D010158:Palatal Obturators; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone